Non-depolarizing neuromuscular blocking agent

Piramal Critical Care

Rocuronium Bromide Injection

Piramal's Rocuronium Bromide Injection is available through the wholesaler or distributor of your choice

Wholesaler / Distributor Name	10 Multi-Dose Vials in a carton: NDC - 66794-228-41 Rocuronium Bromide Injection (5 mL per vial) Catalog numbers	10 Multi-Dose Vials in a carton: NDC - 66794-229-41 Rocuronium Bromide Injection (10 mL per vial) Catalog numbers
AmerisourceBergen	10237058	10237059
Cardinal	5657440	5657457
McKesson	1568310	1568328
Morris & Dickson	905463	905539

ABBREVIATED PRESCRIBING INFORMATION

PRODUCT NAME AND COMPOSITION: Rocuronium bromide injection is a non-depolarizing neuromuscular blocking agent.

Please refer to Full Prescribing Information (FPI) before prescribing.

INDICATIONS: Rocuronium bromide injection is indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation listed in the FPI.

DOSAGE AND ADMINISTRATION: See FPI for full details. Rocuronium bromide injection 5 mL multiple dose vials containing 50 mg rocuronium bromide injection (10 mg/mL). 10 mL multiple dose vials containing 100 mg rocuronium bromide injection (10 mg/mL). Rocuronium bromide injection to be administered only by experienced clinicians or adequately trained individuals supervised by an experienced clinician familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents. Individualize the dose for each patient and peripheral nerve stimulator recommended for determination of drug response and need for additional doses, and to evaluate recovery. Store rocuronium bromide injection with cap and ferrule intact and in a manner that minimizes the possibility of selecting the wrong product. Tracheal intubation: Recommended initial dose is 0.6 mg/kg. Rapid sequence intubation: 0.6 to 1.2 mg/kg. Maintenance doses: Guided by response to prior dose, not administered until recovery is evident. Continuous infusion: Initial rate of 10 to 12 mcg/kg/min. Start only after early evidence of spontaneous recovery from an intubating dose.

CONTRAINDICATIONS: Rocuronium bromide is contraindicated in patients known to have hypersensitivity (e.g., anaphylaxis) to rocuronium bromide or other neuromuscular blocking agents.

COMMON SIDE EFFECTS: Most common adverse reactions (2%) are transient hypotension and hypertension. *See FPI for a complete list.*

WARNINGS AND PRECAUTIONS: Appropriate Administration and Monitoring: Use only if facilities for intubation, mechanical ventilation, oxygen therapy, and an antagonist are immediately available. Anaphylaxis: Severe anaphylaxis has been reported. Consider cross-reactivity among neuromuscular blocking agents. Risk of Death due to Medication Errors: Accidental administration can cause death. Need for Adequate Anesthesia: Must be accompanied by adequate anesthesia or sedation. Residual Paralysis: Consider using a reversal agent in cases where residual paralysis is more likely to occur.

OVERDOSAGE: Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia. The primary treatment is maintenance of a patent airway, controlled ventilation, and adequate sedation until recovery of normal neuromuscular function is assured. Once evidence of recovery from neuromuscular block is observed, further recovery may be facilitated by administration of an anticholinesterase agent in conjunction with an appropriate anticholinergic agent.

For more information, please contact Piramal Customer Service at +1-800-414-1901 during business hours (8 a.m. EST to 5 p.m. EST) or e-mail at pcc.customerservice@piramal.com

- Full prescribing information of Rocuronium Bromide Injection can be seen at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=98255b70-51f9-8d16-e053-2995a90a8f97.
- Adverse events should be reported to Piramal Critical Care at http://pcc-chex.force.com/SiteComplaintForm.
- You are encouraged to report adverse events of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.

"Saving and Improving Patients' Lives."

Piramal Critical Care

Piramal Critical Care, Inc.
3950 Schelden Circle, Bethlehem, PA 18017, USA
Toll Free No.: +1-800-414-1901 www.piramalcriticalcare.com/us/

https://www.linkedin.com/company/piramal-critical-care/

MKT-ROC-0004 SEP 2020